Latest broker research reports
with sell recommendations along with share price targets forecast and upside.
Browse thousands of reports and search by company.
Broker Research reports: Sell reports
for all stocks
TATVA revenue missed our estimates due to significant decline in SDA segment. EBITDA beat our estimates due to lower-than-expected cost of goods sold and operating expenses. However, Adj PAT missed our estimates significantly due to higher-than-expected depreciation, lower than expected other income.
For Q3FY25, the revenue increased to 4.7% YoY (-9.7% QoQ) to INR 14,618 Mn, which missed our estimate by 3.9%. The company YoY growth, driven by toothpaste sales which showed mid-single digit volume growth.
• Company Q3FY25’s earnings performance exceeds our estimates across the board. • For Q3FY25, BIL reported revenue of INR 25,603 Mn (+12.6% YoY/ +5.8% QoQ), which outperformed our estimates by 4.3%.
AU SFB logged a muted performance with a 5% miss on PAT at Rs5.3bn/RoA at 1.5%, mainly on lower other income and elevated provisions owing to ongoing stress in unsecured loans (MFI, Cards, PL) and seasonality impact on the agri and wheels book.
GCPL has been a play on execution for a couple of years now. Our downgrade (to Reduce) after the Q3 business update factored in concerns on slowdown in/waning of execution.
